The Piotroski F-Score calculation for AMD / Advanced Micro Devices, Inc. is shown here. In 2000, Joseph Piotroski published a paper titled "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers." This paper described a method of using data from a company's financial reports to help predict future performance.

The Piotroski F-Score, as it is known, is a 9-point discrete score, where 9 is the best, that ranks companies based on a number of financial factors. To calculate the score, we compare nine factors from the two most recent annual reports. If the change in the factor is "good", then we add one to the score. If the change in the factor is "not good", then we add zero. The following explanations are quoted from the paper.

AMD / Advanced Micro Devices, Inc. Piotroski F-Score

5

Profitability

Current profitability and cash flow realizations provide information about the firm’s ability to generate funds internally. Given the poor historical earnings performance of many value firms, any firm currently generating positive cash flow or profits is demonstrating a capacity to generate funds through operating activities. Similarly, a positive earnings trend is suggestive of an improvement in the firm’s underlying ability to generate positive future cash flows.

ROA : Net Income before Extraordinary Items, scaled by Total Assets at beginning of year

0.01

+1


CFO: Cash Flow from Operations, scaled by Total Assets at beginning of year

0.02

+1


ΔROA: Current Year's ROA less Prior Year's ROA. If this negative, ROA (and therefore profitability) has decreased.

0.17

+1


ACCRUAL: Current Year's Net Income before Extraordinary Items less Cash Flow from Operations, scaled by Total Assets at beginning of year. In short, one if CFO > ROA. The relationship between earnings and cash flow levels is also considered. Earnings driven by positive accrual adjustments (i.e., profits are greater than cash flow from operations) is a bad signal about future profitability and returns. This relationship may be particularly important among value firms, where the incentive to manage earnings through positive accruals (e.g., to prevent covenant violations) is strong.

-0.01

+0

Financial Leverage, Liquidity, and Source of Funds

Three of the nine financial signals are designed to measure changes in capital structure and the firm's ability to meet future debt service obligations. Since many value firms are financially constrained, we assume that an increase in leverage, a deterioration of liquidity, or the use of external financing is a bad signal about financial risk.

ΔLEVER: The historical change in the ratio of long-term debt to average total assets. By raising external capital, a financially distressed firm is signaling its inability to generate sufficient internal funds. In addition, an increase in long-term debt is likely to place additional constraints on the firm’s financial flexibility. An increase in financial leverage is a negative.

-1.17

+1


ΔLIQUID: The historical change in the firm’s current ratio between the current and prior year, where we define the current ratio as the ratio of current assets to current liabilities at fiscal year-end. An improvement in liquidity is a good signal.

-0.12

+0


EQ_OFFER: One if the firm did not issue common equity in the year, zero otherwise. Similar to an increase in long-term debt, financially distressed firms that raise external capital could be signaling their inability to generate sufficient internal funds to service future obligations. Moreover, the fact that these firms are willing to issue equity when their stock prices are likely to be depressed (i.e., high cost of capital) highlights the poor financial condition facing these firms.

28,352,073

+0

Operating Efficiency

The remaining two signals are designed to measure changes in the efficiency of the firm’s operations. These ratios are important because they reflect two key constructs underlying a decomposition of return on assets.

ΔMARGIN: The firm’s current gross margin ratio (gross margin scaled by total sales) less the prior year’s gross margin ratio. An improvement in margins signifies a potential improvement in factor costs, a reduction in inventory costs, or a rise in the price of the firm’s product.

0.11

+1


ΔTURN: The firm’s current year asset turnover ratio (total sales scaled by beginning of the year total assets) less the prior year’s asset turnover ratio. An improvement in asset turnover signifies greater productivity from the asset base. Such an improvement can arise from more efficient operations (fewer assets generating the same levels of sales) or an increase in sales (which could also signify improved market conditions for the firm’s products).

0.22

+1

Peers - Semiconductors and Related Devices (3674)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

20h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

20h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

5 Top Stock Trades for Friday Morning

18h investorplace
President Trump decided to pull out of his meeting with North Korean leader Kim Jong Un and that’s left stocks under pressure. Here’s our top stock trades as a result. (683-0)

Buy Micron (MU) Stock For Value & Growth Outlook

2018-05-23 zacks
Shares of Micron (MU - Free Report) opened lower on Wednesday after two days of gains on the back of some major announcements, including a new deal with Intel (INTC - Free Report) . With that said, let’s dive into why the chip giant’s stock might be worth buying right now. (784-0)

Cowen’s Price Target for Nvidia Corporation Isn’t So Crazy

2018-05-23 investorplace
With nothing more than a quick glance at the headlines, one might conclude it’s just another case of the analyst community playing a game of “chicken,” with NVIDIA Corporation (NASDAQ:NVDA) serving as the proverbial guinea pig. The game? Who’s willing to set the highest target price for NVDA stock. (791-3)

Assessing The AMD Battleground From All Sides

2018-05-23 seekingalpha
There's still a lot of investor interest and passion surrounding the stock, and its future prospects are not yet clear. (897-0)

Intel, Google & Microsoft Discover New Low-Risk Chip Flaws

2018-05-23 zacks
Intel (INTC - Free Report) , Alphabet’s (GOOGL - Free Report) Google and Microsoft (MSFT - Free Report) recently revealed two new security bugs, namely Speculative Store Buffer Bypass or Variant 4 and Rogue System Registry Read. (714-0)

CUSIP: 007903107